This company has been acquired
SGTX Stock Overview
Sigilon Therapeutics, Inc., a preclinical stage biotechnology company, develops functional cures for patients with acute and chronic diseases.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Sigilon Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$22.47 |
52 Week High | US$28.00 |
52 Week Low | US$3.77 |
Beta | 4.11 |
1 Month Change | 5.74% |
3 Month Change | 253.47% |
1 Year Change | 150.50% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -95.03% |
Recent News & Updates
Recent updates
Benign Growth For Sigilon Therapeutics, Inc. (NASDAQ:SGTX) Underpins Stock's 34% Plummet
Apr 17Sigilon Therapeutics GAAP EPS of -$0.44, revenue of $2.88M
Aug 04Sigilon Therapeutics names Philip Ashton-Rickardt as chief scientific officer
Jun 14What Percentage Of Sigilon Therapeutics, Inc. (NASDAQ:SGTX) Shares Do Insiders Own?
Mar 04Sigilon Therapeutics' MPS-1 gene therapy an Orphan Drug in U.S.
Dec 17Shareholder Returns
SGTX | US Biotechs | US Market | |
---|---|---|---|
7D | -2.3% | -0.06% | 2.1% |
1Y | 150.5% | 9.8% | 30.4% |
Return vs Industry: SGTX exceeded the US Biotechs industry which returned 0.6% over the past year.
Return vs Market: SGTX exceeded the US Market which returned 2.4% over the past year.
Price Volatility
SGTX volatility | |
---|---|
SGTX Average Weekly Movement | 127.6% |
Biotechs Industry Average Movement | 11.7% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.7% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SGTX's share price has been volatile over the past 3 months.
Volatility Over Time: SGTX's weekly volatility has increased from 65% to 128% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2015 | 62 | Rogerio Coelho | https://sigilon.com |
Sigilon Therapeutics, Inc., a preclinical stage biotechnology company, develops functional cures for patients with acute and chronic diseases. Its lead product candidate is SIG-002 to replace islet cells for the treatment of type 1 diabetes; and SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-205, SIG-218, SIG-220, and SIG-005, which are to treat the non-neurological manifestations of mucopolysaccharidosis type 1; and SIG-207 is to treat of Fabry disease. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes.
Sigilon Therapeutics, Inc. Fundamentals Summary
SGTX fundamental statistics | |
---|---|
Market cap | US$56.50m |
Earnings (TTM) | -US$30.24m |
Revenue (TTM) | US$17.65m |
3.2x
P/S Ratio-1.9x
P/E RatioIs SGTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
SGTX income statement (TTM) | |
---|---|
Revenue | US$17.65m |
Cost of Revenue | US$29.37m |
Gross Profit | -US$11.71m |
Other Expenses | US$18.53m |
Earnings | -US$30.24m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -12.03 |
Gross Margin | -66.36% |
Net Profit Margin | -171.29% |
Debt/Equity Ratio | 0% |
How did SGTX perform over the long term?
See historical performance and comparison